insights_auto
Prečo akcie AXGN klesli 5,06%?
Preskúmať podrobnejšiechevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
48,75 USD
arrow_downward
-5,06%(-2,60) 1 d.
49,32 USD
arrow_upward
+1,17% (+0,57)bedtimePo uzavretí
Zavreté: 5. 11., 16:00:01 GMT-5 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre AXGN…
Otvoriť
51,62 USD
Vysoká
51,85 USD
Nízka
47,57 USD
Trh. kap.
2,91 mld.
Priem. obj.
1,78 mil.
Objem
1,21 mil.
Max. za 52 týž.
52,91 USD
Min. za 52 týž.
23,00 USD
Výnosy na akciu
-0,68 USD
Beta
1,21
Akcie v obehu
59,73 mil.
Počet zamestnancov
622
Otvoriť
51,62 USD
Vysoká
51,85 USD
Nízka
47,57 USD
Trh. kap.
2,91 mld.
Priem. obj.
1,78 mil.
Objem
1,21 mil.
Max. za 52 týž.
52,91 USD
Min. za 52 týž.
23,00 USD
Výnosy na akciu
-0,68 USD
Beta
1,21
Akcie v obehu
59,73 mil.
Počet zamestnancov
622
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
CNBC
·
pred 33 minútami
Nasdaq sell-off batters Asian chip stocks as SK Hynix, Samsung, Softbank, TSMC tumble
Yahoo Finance
·
pred 32 minútami
S&P 500, Nasdaq, Dow Futures Dip As Investors Step Back From AI And Tech With Nasdaq In Correction Territory — NVDA, AAPL, UBER, SOXX In Focus
The Motley Fool
·
pred 42 minútami
The Nasdaq Composite Just Shattered Its Single-Session Point-Loss Record: 3 Reasons These Elevator-Down Moves May Be Just Beginning
Bloomberg.com
·
pred 2 hodinami
Asian Stocks Brace for Selloff as AI Rout Deepens: Markets Wrap
Profil
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Informácie o subjekte AxoGen, Inc Common Stock
Generálny riaditeľ-
Zamestnanci622
Dátum založenia2002
Hlavné sídloAlachua, Florida, Spojené štáty americké
OdvetvieHealth Care
Industry-